Rewiring Pathology for Precision Drug Discovery and Development

A scientific review of the evidence behind digital pathology and AI’s transformative role in biopharma R&D

Biopharma leaders are no longer asking if they should invest in digital pathology — they’re scaling it enterprise-wide to accelerate R&D and sharpen their competitive advantage.

Through a series of case studies, discover how digital pathology and AI are transforming the precision drug development landscape and learn why pathology is emerging as a foundational data modality for precision medicine, alongside genomics.

Explore 5 key pillars of precision medicine showing tangible outcomes in:

• Biomarker Discovery – Unlocking novel, multimodal biomarkers and accelerating target identification from routine histology
• Spatial Biology – Profiling the tumor microenvironment (TME) to understand resistance mechanisms and uncover new targets
• Preclinical Safety – Delivering quantitative toxicology assessments that drive faster, more confident go/no-go decisions
• Patient Stratification – Enhancing clinical trial design and optimizing enrollment
• AI-Based Companion Diagnostics (CDx) – Increasing success rates for next-generation targeted therapies and expanding the addressable patient population

Digital pathology is no longer just an efficiency play — it’s a strategic lever to speed discovery, improve trial outcomes, and build high-value proprietary data assets. Read the report and find out how.